



13:00-13:25 **Targeting mEGFR with 3rd Generation TKIs**

Se-Woong Oh

Yuhan Corporation, Chief Scientific Officer

[Recent Activities]

- Project Leader of Lazertinib (a 3rd-generation EGFR TKI) Development
- Leading Open Innovation with Biotech, Pharma, and Academia
- President of the Korean Society of Non-Clinical Study (2018-2019)4)

[Research Interests]

- Drug Discovery & Development, Immuno-Oncology, Translational Science